Not Medicare Enrolled

Dr. Jeffrey Sosman, MD

Medical Oncology · Chicago, IL
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
675 N SAINT CLAIR ST STE 21-100, Chicago, IL 60611
3126950990
In practice since 2006 (19 years)
NPI: 1699862706 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sosman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sosman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Sosman

Dr. Jeffrey Sosman is a medical oncology specialist in Chicago, IL, with 19 years of NPI registration. Based on federal Medicare data, Dr. Sosman performed 3,853 Medicare services across 329 unique beneficiaries.

Between the years covered by Open Payments, Dr. Sosman received a total of $57,044 from 18 pharmaceutical and/or device companies across 66 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Sosman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 23% volume in IL $57,044 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,853
Medicare services
Top 23% in IL for medical oncology
329
Unique beneficiaries
$39
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~203 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Daratumumab injection (Darzalex)
An injection containing daratumumab and hyaluronidase-fihj administered under the skin.
2,700 $37 $170
Bortezomib injection, 0.1 mg
Administration of a 0.1 mg dose of bortezomib medication via injection.
393 $6 $174
Dexamethasone injection (steroid)
An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram.
180 $0 $1
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
174 $96 $323
Anti-nausea injection (Aloxi/palonosetron) 120 $1 $76
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
98 $148 $434
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
61 $107 $940
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
31 $13 $143
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
27 $60 $326
Telephone medical discussion, 21-30 minutes
A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone.
25 $105 $250
New patient office visit, complex (60-74 min) 16 $184 $625
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
14 $12 $88
Intravenous infusion of new drug or substance, 1 hour or less
This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less.
14 $54 $464
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.9% high complexity
89.9% medium
8.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$57,044
Total received (2018-2024)
Avg $8,149/year across 7 years
Top 13% in IL for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
18
Companies
66
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$23,539 (41.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$19,850 (34.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$13,656 (23.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,087
2023
$688
2022
$5,172
2021
$3,100
2020
$975
2019
$2,763
2018
$43,260

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca UK Limited
$812
Iovance Biotherapeutics, Inc.
$274
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$20,156
F. Hoffmann-La Roche AG
$14,672
Genentech USA, Inc.
$4,759
Takeda Pharmaceuticals U.S.A., Inc.
$4,576
JAZZ PHARMACEUTICALS INC.
$3,000
AstraZeneca UK Limited
$2,375
PFIZER INC.
$2,169
AVEO Pharmaceuticals, Inc.
$2,100
EISAI INC.
$2,040
Clinigen Inc
$290
Iovance Biotherapeutics, Inc.
$274
CLINIGEN, INC.
$157
Foundation Medicine, Inc.
$130
Prometheus Laboratories Inc.
$114
Array BioPharma Inc.
$106
Clinigen, Inc.
$89
Merck Sharp & Dohme Corporation
$21
VENTANA MEDICAL SYSTEMS, INC.
$16
Top 3 companies account for 69.4% of all-time payments
Associated products mentioned in payments ›
Amtagvi · BAVENCIO · BENCHMARK IHC/ISH PLATFORMS & REAGENTS · Braftovi · FOTIVDA · FOUNDATIONACT · IMFINZI · KEYTRUDA · LYNPARZA · Lenvima · Non-Covered Product · OPDIVO · PROLEUKIN · Proleukin · TECENTRIQ · Zelboraf
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (41%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.

Looking for a medical oncology specialist in Chicago?
Compare medical oncologists in the Chicago area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
78
Per 100K population
1.5
County median income
$81,797
Nearest hospital
NORTHWESTERN MEMORIAL HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment — Not enrolled N/A
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Sosman is a mixed practice specialist, with above-average Medicare volume (top 23% in IL), with speaking/promotional industry engagement in the top 13% of IL peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Sosman experienced with daratumumab injection (darzalex)?
Based on Medicare claims data, Dr. Sosman performed 2,700 daratumumab injection (darzalex) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sosman receive payments from pharmaceutical companies?
Yes. Dr. Sosman received a total of $57,044 from 18 companies across 66 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sosman's costs compare to other medical oncologists in Chicago?
Dr. Sosman's average Medicare payment per service is $39. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sosman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →